Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 29, 2015Clinical Cancer ResearchOpen Access

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSherene LoiUniversité Paris-SudSDSathana DushyanthenThe University of MelbournePBPaul A. BeavisThe University of Melbourne

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Loi et al. (2015) studied this question.

synapsesocial.com/papers/6a07f276686e45fdbcfe0bcahttps://doi.org/10.1158/1078-0432.ccr-15-1125
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing1995 · 112,744 citations
  2. 2Comprehensive molecular portraits of human breast tumours2012 · 12,630 citations
  3. 3Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma2011 · 4,539 citations
  4. 4MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC2009 · 35 citations
  5. 5The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors2006 · 638 citations